Cognition Therapeutics, Inc. Depreciation
Cognition Therapeutics, Inc. (CGTX) reported Depreciation of $83.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2023-03-23
- Cognition Therapeutics, Inc. depreciation for fiscal 2022 was $83.00K, a 10.75% decline from fiscal 2021.
- Cognition Therapeutics, Inc. depreciation for fiscal 2021 was $93.00K, a 55.00% increase from fiscal 2020.
- Cognition Therapeutics, Inc. depreciation for fiscal 2020 was $60.00K.
| Period end | Depreciation 12 month |
|---|---|
| 2022-12-31 | $83.00K 10-K · filed 2023-03-23 |
| 2021-12-31 | $93.00K 10-K · filed 2023-03-23 |
| 2020-12-31 | $60.00K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |